Sharp decrease in babies born with asphyxia and brain damage at Nordic clinics with new surveillance method

The number of babies born with severe oxygen deficiency, asphyxia and brain damage has decreased sharply at the university clinics in the Nordic countries that use ST Analysis, a rather new Swedish method for fetal surveillance during labour. New statistics show a strong increase in safety at deliveries during the last few years. The new results were reported today at the 36th Nordic Congress of Obstetrics and Gynecology in Reykjavik, Iceland (NFOG).

Read more

First STAN fetal monitoring centre opens in the USA

The first STAN centre in the USA opened on Monday October 22nd in the labour and delivery unit at the Community Regional Medical Center and the University of California, Fresno Medical Education Program. The system, developed in Sweden by Neoventa Medical, is available in Europe since 2000 and in use in more than
350 labour delivery units.

Read more

Philips signs cooperation agreement with Neoventa

Dutch company, Philips Medical Systems has signed a cooperation agreement with Swedish company, Neoventa Medical AB. The agreement means that the companies’ foetal monitoring systems will be compatible, and it will be possible to receive ST data in OB TraceVue from births monitored with STAN, which until present represent close to one million. “The agreement is a major success for both Neoventa and Philips,” says Neoventa’s CEO, Jan Stålemark, “It is further confirmation that the STAN method has been widely accepted.”

Read more

Investor Growth Capital and CapMan invest in Neoventa Medical

Investor Growth Capital and CapMan invest in Neoventa Medical AB, a Swedish medical technology company within the area of fetal monitoring. Following these investments, CapMan and Investor Growth Capital will each have an approximately 30% stake in Neoventa. The majority of the other shares will be retained by SEB Företagsinvest. The new shareholder structure will together secure a total capital injection of SEK 75 million that will finance the next phase of growth for Neoventa with a focus on the US market.

Read more

Neoventa introduces unique fetal heart monitor to the U.S. market

The U.S. Food and Drug Admistration (FDA) has approved the STAN® S31 Fetal heart monitor Pre-Market Approval (PMA) application. STAN from Neoventa Medical is the first fetal monitor proven to reduce the risk of brain injury during labor.

Read more

FDA Advisory Panel Unanimously Recommends Approval of the STAN Fetal heart monitor from Neoventa Medical

The U.S. Food and Drug Administration’s (FDA) Obstetrics and Gynecology Advisory Panel voted Thursday to recommend approval of the STAN® S31 Fetal heart monitor Pre-Market Approval (PMA) application. STAN helps clinicians identify babies at risk due to oxygen deficiency during labor. It also reduces the number of unnecessary operative interventions.

Read more
Page 12 of 12 «...89101112

# #